GERON CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.8 USD | -2.06% |
|
-3.31% | +80.09% |
| May. 03 | Wedbush Adjusts Geron's Price Target to $7 From $6, Keeps Outperform Rating | MT |
| May. 02 | Geron Shares Decline After Q1 Loss Widens | MT |
Presenter SpeechOlivia Bloom (Executives)Good afternoon, everyone. Welcome to the Geron Invest...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Calendar
2024-07-31
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
3.8
USD
Average target price
6.071
USD
Spread / Average Target
+59.77%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +80.09% | 2.25B | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- GERN Stock
- News Geron Corporation
- Transcript : Geron Corporation - Special Call